Categories Analysis, Technology

Stock Watch: Is this the right time to invest in DocuSign (DOCU)?

The company has expanded its partnership with Microsoft to offer new DocuSign Agreement Cloud integrations and capabilities across the latter's business solutions

Like most tech companies, DocuSign, Inc. (NASDAQ: DOCU) successfully leveraged the widespread adoption of digital technology in the last two years but the momentum slowed in recent months and the e-signature firm is currently enhancing its go-to-market capabilities to boost sales.

The San Francisco-headquartered company’s stock is trading at the lowest level in more than two-and-half years, with most of the losses coming this year. The stock, one of the worst affected by the recent sell-off, further declined after last week’s earnings report. The mixed first-quarter results and the management’s weak outlook call for caution as far as investing in DOCU is concerned, though the stock is expected to make strong gains in the long term – experts see double-digit growth in 12 months.

Hold It?

It is not a good time to either buy or sell the stock, rather keeping an eye on it would help investors take the right decision at the right time. The fact that the company does not pay dividends, and dilutions due to heavy stock-based compensations make it less attractive. But DocuSign is unlikely to disappoint long-term investors since the digital shift is likely to accelerate further irrespective of market challenges. Having gained about 70% of the e-signature market share, supported by a rapidly growing subscriber base, DocuSign’s long-term prospects look bright.

Read management/analysts’ comments on quarterly reports 

The company recently launched what it calls CLM Essentials, which allows customers to get started with Contract Lifecycle Management in a hassle-free manner. It has also expanded the global strategic partnership with Microsoft Corp. (NASDAQ: MSFT) to offer new DocuSign Agreement Cloud integrations and capabilities across Microsoft’s business solutions. DocuSign is on track to further expand the portfolio in the coming months with additional offerings. In an effort to balance growth and profitability, the management is streamlining the business through initiatives like slowing down hiring.

DocuSign Q1 2023 earnings infographic

“We’re confident in our strategy and path to becoming a $5 billion revenue company. DocuSign continues to be the clear market leader in the electronic signature space, and we are excited about our progress in defining the broader Agreement Cloud category as well. Our dedication to innovation and our investments in attracting high-caliber talent position us to build upon our leading market share,” said DocuSign’s CEO Dan Springer at the post-earnings meet.

The economic uncertainty from the Ukraine war and other macro challenges, including elevated inflation, is putting pressure on sales, especially in Europe where the company has a strong presence. Another challenge facing the company is growing competition from Adobe Sign and HelloSign, which is owned by Dropbox, Inc. (NASDAQ: DBX).

Mixed Results

After beating estimates in every quarter since mid-2019, DocuSign’s earnings missed expectations in the most recent quarter. Unadjusted profit slipped to $0.38 per share in the first quarter of 2023 from $0.44 per share last year. On the other hand, revenues rose to $589 million amid strong billings growth, supported by a double-digit increase in the core subscription business. However, the management sees sales growth decelerating in the coming quarters.

Should you buy Oracle stock ahead of next week’s earnings?

DocuSign’s stock closed the last trading session slightly above $60, which is down 80% from the all-time highs of September 2021. The current valuation is also far below the long-term average.


Stocks you may like:

Apple (AAPL) Stock

Microsoft (MSFT) Stock

Alphabet (GOOGL) Stock

International Business Machines Corp. (IBM) Stock


Most Popular

Cost reduction has become a priority for FedEx (FDX) after a challenging quarter

Shares of FedEx Corporation (NYSE: FDX) were up 1% on Tuesday. The stock has dropped 44% year-to-date and 34% over the past 12 months. The company delivered mixed results for

Prime Medicine is the next big biotech to pursue IPO. Here’s all you need to know

After a soft start to the year, the IPO market has witnessed muted activity so far though a few big companies entered the stock market. On the heels of AIG

Stock Watch: Is Darden Restaurants a good buy after earnings?

After a prolonged slowdown, the restaurant industry is returning to normal patterns but macroeconomic uncertainties and high inflation are currently playing spoilsport for it. While the pandemic-related slump forced many

Add Comment
Viewing Highlight